

# Celgene Limited

## Methodological Statement

*summarizing the methodologies used in preparing the disclosure of transfers of value to health professionals and healthcare organisations pursuant to Clauses 19, 20, 21, 22, 23 and 24 of the ABPI Code of Practice for the Pharmaceutical Industry 2019, the “Code”*

### **Introduction**

Celgene Limited (**Celgene**) is a company which is part of the Bristol-Myers Squibb group of companies having been acquired in November 2019. During the time of this disclosure period Celgene was part of the Celgene Corporation<sup>1</sup> group of companies. Celgene conducts sales, marketing and associated activities for various medicinal products in the United Kingdom. Celgene and Celgene Corporation also collaborate in research and development activities conducted in the United Kingdom.

In the course of these activities, Celgene and Celgene Corporation engage with health professionals<sup>2</sup> whose registered practice addresses are in the United Kingdom and with healthcare organisations<sup>3</sup> based in the United Kingdom.

The disclosures that Celgene has submitted to the Association of the British Pharmaceutical Industry represent the transfers of value (**ToV**)<sup>4</sup> that Celgene, and companies in the Celgene Corporation group of companies<sup>5</sup> have made to such health professionals and healthcare organisations during 2019 insofar as those ToV fall within Celgene’s disclosure obligations as defined in Clauses 19, 20, 21, 22, 23 and 24 of the Code.

### **Statement for disclosure of 2019 data during the COVID-19 pandemic in 2020**

As part of the pharmaceutical industry’s annual disclosure of transfers of value to HCPs, ORDMs and HCOs via the Disclosure UK platform and in order to ensure accuracy of the published data, the ABPI writes to all of the HCPs, ORDMs and HCOs named in companies’ disclosure data ahead of its publication on Disclosure UK at the end of June. (Over 20,000 in June 2019)

---

<sup>1</sup> For the purposes of this document alone, the term “Celgene Corporation” refers to Celgene Corporation and all its affiliates and subsidiaries in the Celgene Corporation group of companies

<sup>2</sup> as defined by Clause 1.4 of the Code and including “*other relevant decision makers*” as defined by Clause 1.5 of the Code

<sup>3</sup> as defined by Clause 1.9 of the Code

<sup>4</sup> as defined by Clause 1.10 of the Code

Given the unprecedented pressure on the NHS and health care professionals in responding to the COVID-19 pandemic, in April 2020 the ABPI and PMCPA agreed that it would not be appropriate for industry to write to HCPs, ORDMs or HCOs to request that disclosure data be reviewed. Doing so would add additional work for NHS professionals at this time. To avoid this, and in-line with guidance provided by the ABPI, Celgene's 2019 transfer of value data has been published on Disclosure UK in aggregate.

### ***Commitment to transparency***

The pharmaceutical industry is committed to preserving the integrity of Disclosure UK and transparency in our interactions with HCPs, ORDMs and HCOs. The ABPI continues to explore how the full disaggregated 2019 data can be submitted to Disclosure UK in line with data from previous years.

### ***Publication of disaggregated 2019 disclosure data on Celgene company website***

The below link is included to provide access to the disaggregated 2019 disclosure data, per the ABPI Disclosure UK 2019 guidelines:

<https://www.celgene.co.uk/responsibility/efpia-spend-transparency-disclosure/>

### ***Methodology***

The data upon which Celgene's disclosures are based has been collected and compiled by Celgene Corporation's Spend Transparency Office based in Summit, New Jersey. The Spend Transparency Office is responsible for the collection of the ToV disclosure data for ToVs to health professionals and healthcare organisations made by any company in the Celgene Corporation group of companies worldwide in accordance with relevant local laws and codes of practice.

In preparation for compliance with Clauses 19 – 24 of the Code, the Spend Transparency Office first identified all the possible sources of information within the Celgene Corporation group finance system and held by third party vendors that could identify any and all payments made by any company in the Celgene Corporation group of companies to health professionals and healthcare organisations based in the United Kingdom. Using information supplied by IQVIA Health, verified and supplemented by various commercial operations resources within Celgene and the Celgene Corporation group of companies, publicly available information and information from third party vendors, the Spend Transparency Office narrowed down the list of payees to those that fell within the definitions of health professional, other relevant decision makers and healthcare organisation, as set out in Clauses 1.4, 1.5 and 1.9 of the Code. Celgene used the IQVIA OneKey Code as a unique identifier of any given health professional where available.

Based on this data Celgene has endeavoured to disclose to the ABPI for publication on its central platform all direct and indirect ToVs made between 1 January 2019 and 31 December 2019 inclusive that fall within

its disclosure obligations as set out in Clauses 19 – 24 of the Code, applying the relevant definitions contained therein.

The ToVs upon which Celgene's disclosure data is based is any direct or indirect ToV, whether monetary, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development and/or sale of prescription only medicinal products for human use. This includes, but is not limited to, payments of fees for services, consultancy and associated expenses, registration fees, sponsorships, grants, donations, joint working, travel, accommodation and ToVs related to pre-clinical and clinical development.

### ***Joint Working***

Joint working disclosure is based on ToV made in the relevant disclosure calendar year and not the lifetime of the joint working project.

### ***Third parties***

Celgene has included in its contractual templates, which it contracts with third parties, a binding clause requiring the third party to notify to Celgene all ToVs made to health professionals and healthcare organisations. Celgene has endeavoured to include all such ToVs so notified within the scope of its disclosures to the ABPI for the relevant calendar year.

### ***Distributors***

In the United Kingdom, Celgene does not market its products through distributors.

### ***Cross border transactions***

Celgene Spend Transparency Office has worked with Celgene Corporation's functions and affiliates worldwide to capture data relating to ToV made by them to health professionals with their practice address in the United Kingdom and healthcare organisations based in the United Kingdom. Celgene has endeavoured to include all such transfers of value within its disclosures to the ABPI.

### ***Consent***

Celgene and Celgene Corporation have endeavoured to seek consent from all health professionals to disclosure on an individual basis, naming the recipient and identifying the ToV. To this end, Celgene and Celgene Corporation have incorporated a clause to this effect in the contractual templates on the basis of which, pursuant to Celgene's relevant policies, all such engagements should proceed.

In circumstances where a health professional declines to give, or subsequently withdraws, consent to disclosure on an individual basis of ToV during the reporting calendar year, Celgene has disclosed all ToVs made to that health professional in aggregate.

***Disclosure in aggregate***

Where the recipient of a ToV cannot be disclosed for legal reasons, including where a health professional has declined to give, or subsequently withdraws, consent to disclosure on an individual basis, Celgene has disclosed those ToVs on an aggregate basis.

Celgene has also disclosed on an aggregate basis ToV falling within the definition of “*Research and Development Transfers of Value*” pursuant to Clause 23.2 of the Code.

***Currency***

Celgene has made its disclosures in sterling, using a published monthly average exchange rate with sterling for those payments made in any other currency.

***Tax***

Celgene has made its disclosures relating to direct ToVs exclusive of all applicable taxes. It is possible, however, that some indirect ToVs made by third party vendors have been reported to us inclusive of taxes.

***Date methodology***

Celgene has made its disclosures relating to cash payments by reference to the payment date. In circumstances where ToVs represent benefits in kind, Celgene has made its disclosures by reference to the date of the event/activity where the ToV occurred.

***Multi-year contracts***

Where multi-year contracts are in place, Celgene will disclose each ToV in the reporting calendar year the ToV took place.

Prepared by

Celgene Limited, Stockley Park, United Kingdom

Celgene Corporation, Spend Transparency Office, Summit, New Jersey, United States of America

On 30 June 2020